New York bill A04054 mandates that businesses with alcohol and cannabis licenses for on-premises consumption must have opioid antagonists available.

New York bill A04054 amends the alcoholic beverage control law and the cannabis law to require businesses with retail licenses for on-premises alcohol consumption and adult-use on-site cannabis consumption to have opioid antagonists available. These antagonists, which include naloxone and narcan, are medications approved by the Department of Health and the FDA that counteract the effects of opioids. The bill aims to ensure that these potentially life-saving medications are accessible in environments where alcohol and cannabis are consumed on-site.

New York bill A04054 mandates that businesses with alcohol and cannabis licenses for on-premises consumption must have opioid antagonists available.

New York bill A04054 amends the alcoholic beverage control law and the cannabis law to require businesses with retail licenses for on-premises alcohol consumption and adult-use on-site cannabis consumption to have opioid antagonists available. These antagonists, which include naloxone and narcan, are medications approved by the Department of Health and the FDA that counteract the effects of opioids. The bill aims to ensure that these potentially life-saving medications are accessible in environments where alcohol and cannabis are consumed on-site.